Iron Drugs Market size to grow by USD 3,552.86 million from 2022 to 2027: A growing number of CKD dialysis centers is an emerging trend - Technavio

NEW YORK, June 28, 2023 /PRNewswire/ -- The iron drugs market size is forecast to increase by USD 3,552.86 million from 2022 to 2027, at a CAGR of 9.41%, according to the recent market study by Technavio. The growth of the market will be driven by the growing prevalence of iron deficiency globally, growing awareness about the importance of iron in maintaining overall health, and the growing geriatric population. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download The Sample Report

Technavio categorizes the global iron drugs market Vendor Analysis:

The iron drugs market is highly competitive, with several major players competing for market share. To remain competitive in the iron drugs market, these companies are investing in research and development to develop new and innovative iron products, as well as improve existing products. Furthermore, they are also focusing on expanding their geographic presence and distribution networks to reach more customers and increase their market share. Companies are ensuring that their products comply with regulatory requirements and safety standards and that they are marketed effectively to healthcare professionals and patients.

Technavio has extensively analyzed 15 major vendors, including Abbott Laboratories, AbbVie Inc., Alinter Group Ltd., Alora Pharmaceuticals LLC, Covis Pharma GmbH, Daiichi Sankyo Co. Ltd., DSE Health Care Solutions Inc., GlaxoSmithKline Plc, Hiral Labs Ltd., McKesson Corp., NovaFerrum, Pharmacosmos AS, Procter and Gamble, Reckitt Benckiser Group Plc, Rockwell Medical Inc., Sanofi SA, Shield Therapeutics plc, Vifor Pharma Management Ltd., Zydus Lifesciences Ltd., and Breckenridge Pharmaceutical Inc. Download The Sample Report

Vendor Offerings -

• McKesson Corp. - The company offers iron drugs such as Hemral Plus under the subsidiary Hiral Health.
• Daiichi Sankyo Co. Ltd. - The company offers iron drugs such as Feraheme ferumoxytol injection for Intravenous.
• DSE Health Care Solutions Inc. - The company offers iron drugs such as Injectafer ferric carboxymaltose injection.

Charts & data tables about market and segment sizes for a historic period of five years (2017-2021), and a forecast period (2023-2027) have been covered in this report. Download The Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Market Segmentation

The iron drugs market report extensively covers market segmentation by product (oral drug and IV drug), age group (adult and pediatric), and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

The market share growth by the oral drug segment will be significant during the forecast period. The drug that is taken orally to treat iron deficiency anemia is known as an oral drug. They are well-tolerated by most patients, and they are mostly available by prescription or over-the-counter. Furthermore, ferrous sulfate, ferrous gluconate, ferrous fumarate, and iron polysaccharide complex are different types of oral iron supplements. The most used type of oral iron supplement is ferrous sulfate. Hence, these factors are expected to increase the segment growth during the forecast period.

Market Dynamics:

Key Drivers

The growing prevalence of iron deficiency is the key factor driving the growth of the market. Iron deficiency affects people of all ages and sexual orientations. Teenage girls are more affected by iron deficiencies. Furthermore, the main causes of iron deficiency are menstrual blood loss, infections, and parasite infestations. Iron deficiency can be caused due to several factors such as lack of nutrients, a rise in demand, or blood loss due to any cause. In addition, more than half of the world's undernourished population is living in India. Hence, the growing prevalence of iron deficiency is one of the major drivers which is expected to the market growth during the forecast period.

Major Trends

A growing number of CKD dialysis centers in emerging economies is the primary trend. The growing prevalence of CKD in emerging economies such as China, India, and Brazil is motivating renal anemia therapeutics vendors to invest in the market. For example, in 2021, NephroPlus, Asia's dialysis network, announced a USD 25 million investment in India to pursue growth opportunities in India and international markets. New growth opportunities for the vendors in the market are being created in emerging economies by these developments in dialysis centers. Hence, these factors are expected to drive the market growth during the forecast period.

Key Challenges

The high cost of IV iron therapies is a major challenge to the growth of the market. There are several advantages of IV iron therapies over oral iron drugs, but the high price is a major challenge. As a result, there is a negative effect on their adoption as people may choose low-cost alternatives. For example, the total cost of treatment for iron infusion for severe anemia per year for an individual is around USD 16,000, excluding out-of-pocket expenses of USD 6,500. The high initial cost of ferric carboxymaltose is posing a challenge to the market although it is more cost-effective in the long run. Hence, these high costs are expected to hamper market growth during the forecast period.

To get detailed insights about inclusions and exclusions, buy the report

What are the key data covered in this iron drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the iron drugs market between 2023 and 2027
• Precise estimation of the size of the iron drugs market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the iron drugs market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of iron drugs market vendors

Gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Related Reports

The oncology drugs market size is estimated to grow at a CAGR of 11.99% between 2023 and 2027. The market size is forecast to increase by USD 151.84 billion. Furthermore, this report extensively covers market segmentation by therapy (targeted therapy, immunotherapy, hormonal therapy, and chemotherapy), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The Increasing prevalence of cancer is a key factor driving the market growth during the forecast period.

The acne drugs market size is estimated to grow at a CAGR of 3.46% between 2022 and 2027. The acne drugs market size is forecast to increase by USD 907.11 million. Furthermore, this report extensively covers market segmentation by type (prescription drugs and OTC drugs), route of administration (topical and oral), and geography (North America, Europe, Asia, and the Rest of the World). The emergence of improved diagnostic modalities is a key factor driving the market growth during the forecast period.

Table of Contents

1 Executive Summary

• 1.1 Market Overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Age Group
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global iron drugs market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on global iron drugs market 2017 - 2021 ($ million)

• 4.2 Product Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)

• 4.3 Age Group Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Age Group Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product - Market share 2022-2027 (%)

• 6.2 Comparison by Product 
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product

• 6.3 Oral drug - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Oral drug - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral drug - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral drug - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral drug - Year-over-year growth 2022-2027 (%)

• 6.4 IV drug - Market size and forecast 2022-2027 
• Exhibit 38: Chart on IV drug - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on IV drug - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on IV drug - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on IV drug - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Product 
• Exhibit 42: Market opportunity by Product ($ million)
• Exhibit 43: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Age Group

• 7.1 Market segments
• Exhibit 44: Chart on Age Group - Market share 2022-2027 (%)
• Exhibit 45: Data Table on Age Group - Market share 2022-2027 (%)

• 7.2 Comparison by Age Group 
• Exhibit 46: Chart on Comparison by Age Group
• Exhibit 47: Data Table on Comparison by Age Group

• 7.3 Adult - Market size and forecast 2022-2027 
• Exhibit 48: Chart on Adult - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Data Table on Adult - Market size and forecast 2022-2027 ($ million)
• Exhibit 50: Chart on Adult - Year-over-year growth 2022-2027 (%)
• Exhibit 51: Data Table on Adult - Year-over-year growth 2022-2027 (%)

• 7.4 Pediatric - Market size and forecast 2022-2027 
• Exhibit 52: Chart on Pediatric - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Pediatric - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Pediatric - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Pediatric - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Age Group 
• Exhibit 56: Market opportunity by Age Group ($ million)
• Exhibit 57: Data Table on Market opportunity by Age Group ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 59: Chart on Market share by geography 2022-2027 (%)
• Exhibit 60: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 61: Chart on Geographic comparison
• Exhibit 62: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Japan - Market size and forecast 2022-2027 
• Exhibit 83: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.9 China - Market size and forecast 2022-2027 
• Exhibit 87: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.10 Germany - Market size and forecast 2022-2027 
• Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.11 France - Market size and forecast 2022-2027 
• Exhibit 95: Chart on France - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on France - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on France - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on France - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 99: Market opportunity by geography ($ million)
• Exhibit 100: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 101: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 102: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 103: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 104: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 105: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 106: Matrix on vendor position and classification

• 12.3 Abbott Laboratories
• Exhibit 107: Abbott Laboratories - Overview
• Exhibit 108: Abbott Laboratories - Business segments
• Exhibit 109: Abbott Laboratories - Key news
• Exhibit 110: Abbott Laboratories - Key offerings
• Exhibit 111: Abbott Laboratories - Segment focus

• 12.4 AbbVie Inc.
• Exhibit 112: AbbVie Inc. - Overview
• Exhibit 113: AbbVie Inc. - Product / Service
• Exhibit 114: AbbVie Inc. - Key news
• Exhibit 115: AbbVie Inc. - Key offerings

• 12.5 Covis Pharma GmbH
• Exhibit 116: Covis Pharma GmbH - Overview
• Exhibit 117: Covis Pharma GmbH - Product / Service
• Exhibit 118: Covis Pharma GmbH - Key offerings

• 12.6 Daiichi Sankyo Co. Ltd. 
• Exhibit 119: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 120: Daiichi Sankyo Co. Ltd. - Product / Service
• Exhibit 121: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 122: Daiichi Sankyo Co. Ltd. - Key offerings

• 12.7 GlaxoSmithKline Plc
• Exhibit 123: GlaxoSmithKline Plc - Overview
• Exhibit 124: GlaxoSmithKline Plc - Business segments
• Exhibit 125: GlaxoSmithKline Plc - Key news
• Exhibit 126: GlaxoSmithKline Plc - Key offerings
• Exhibit 127: GlaxoSmithKline Plc - Segment focus

• 12.8 Hiral Labs Ltd.
• Exhibit 128: Hiral Labs Ltd. - Overview
• Exhibit 129: Hiral Labs Ltd. - Product / Service
• Exhibit 130: Hiral Labs Ltd. - Key offerings

• 12.9 McKesson Corp.
• Exhibit 131: McKesson Corp. - Overview
• Exhibit 132: McKesson Corp. - Business segments
• Exhibit 133: McKesson Corp. - Key offerings
• Exhibit 134: McKesson Corp. - Segment focus

• 12.10 Pharmacosmos AS
• Exhibit 135: Pharmacosmos AS - Overview
• Exhibit 136: Pharmacosmos AS - Product / Service
• Exhibit 137: Pharmacosmos AS - Key offerings

• 12.11 Procter and Gamble
• Exhibit 138: Procter and Gamble - Overview
• Exhibit 139: Procter and Gamble - Business segments
• Exhibit 140: Procter and Gamble - Key offerings
• Exhibit 141: Procter and Gamble - Segment focus

• 12.12 Reckitt Benckiser Group Plc 
• Exhibit 142: Reckitt Benckiser Group Plc - Overview
• Exhibit 143: Reckitt Benckiser Group Plc - Business segments
• Exhibit 144: Reckitt Benckiser Group Plc - Key offerings
• Exhibit 145: Reckitt Benckiser Group Plc - Segment focus

• 12.13 Rockwell Medical Inc. 
• Exhibit 146: Rockwell Medical Inc. - Overview
• Exhibit 147: Rockwell Medical Inc. - Product / Service
• Exhibit 148: Rockwell Medical Inc. - Key offerings

• 12.14 Sanofi SA
• Exhibit 149: Sanofi SA - Overview
• Exhibit 150: Sanofi SA - Business segments
• Exhibit 151: Sanofi SA - Key news
• Exhibit 152: Sanofi SA - Key offerings
• Exhibit 153: Sanofi SA - Segment focus

• 12.15 Shield Therapeutics plc 
• Exhibit 154: Shield Therapeutics plc - Overview
• Exhibit 155: Shield Therapeutics plc - Product / Service
• Exhibit 156: Shield Therapeutics plc - Key offerings

• 12.16 Vifor Pharma Management Ltd. 
• Exhibit 157: Vifor Pharma Management Ltd. - Overview
• Exhibit 158: Vifor Pharma Management Ltd. - Product / Service
• Exhibit 159: Vifor Pharma Management Ltd. - Key news
• Exhibit 160: Vifor Pharma Management Ltd. - Key offerings

• 12.17 Zydus Lifesciences Ltd. 
• Exhibit 161: Zydus Lifesciences Ltd. - Overview
• Exhibit 162: Zydus Lifesciences Ltd. - Business segments
• Exhibit 163: Zydus Lifesciences Ltd. - Key offerings
• Exhibit 164: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 165: Inclusions checklist
• Exhibit 166: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 167: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 168: Research methodology
• Exhibit 169: Validation techniques employed for market sizing
• Exhibit 170: Information sources

• 13.5 List of abbreviations
• Exhibit 171: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio